Quanterix Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.9%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$169.9Mnext fiscal year
FY EPS (est.)
-$1.23next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly36.4MTarget: 169000000 to 174000000
GAAP Gross Margin Quarterly4,270.0%Target: 41% to 45%
Adjusted Gross Margin (Non-GAAP) Quarterly5,090.0%Target: 49% to 53%
Cash Flow Breakeven Target AnnuallyTarget: Achieve cash flow breakeven in H2 2026
Watch Items
- FDA 510(k) Decision on Alzheimer's Multi-Marker Blood TestTrigger: FDA clearance decision expected in H2 2026Action: Monitor regulatory announcements and prepare commercial launch plans upon approval.
- Academic and Pharmaceutical End-Market Demand SoftnessTrigger: Organic revenue declines (Simoa down 21%, Spatial Biology down 26% in Q1 2026)Action: Refocus sales resources toward pharma end-markets and optimize commercial effectiveness.
- Akoya Biosciences Integration and Cost SynergiesTrigger: Realization of the full $85 million in annualized cost synergiesAction: Track G&A consolidation, manufacturing integration, and transition from cost-cutting to growth investments.
Research as of 20 Jun 2026